企業概要
GeneDx Holdings Corp. is a genomics enterprise that delivers specialized genetic testing services, with a primary focus on pediatric and rare disease diagnostics utilizing whole exome and genome sequencing technologies. The company operates within the Healthcare sector, specifically inside the Diagnostics & Research industry, where it provides critical data and information services alongside the development of an AI-based platform for next generation sequencing. As of the latest available data, the corporation holds a market capitalization of $1.92B and generates annual revenue totaling $427.54M, supported by an operational workforce of 1,300 employees. These financial metrics indicate that GeneDx Holdings Corp. occupies a significant position in the healthcare diagnostics landscape, possessing substantial revenue streams that justify its nearly two-billion-dollar valuation despite recent earnings challenges.
財務健全性
The company reported revenue of $427.54M over the trailing twelve months, yet recorded a net income of -$21,021,000 and an EBITDA of $12.65M, a disparity that reveals a substantial cost structure burden where operating expenses significantly erode profitability before reaching the bottom line. Despite the negative net income, the entity maintains robust free cash flow of $38.06M, which provides essential financial flexibility to fund ongoing operations, invest in research and development, or manage capital allocation without immediate reliance on external equity financing. Analysis of the profit margins shows a gross margin of 69.7%, indicating strong pricing power and efficient production costs, while the operating margin stands at -10.6% and the profit margin at -4.9%, signaling that high overhead costs or specific one-time charges are currently suppressing operational efficiency. The balance sheet presents a complex picture with $171.28M in cash assets offsetting $113.17M in debt, resulting in a debt-to-equity ratio of 36.72 which suggests a highly leveraged capital structure relative to equity. Short-term liquidity is supported by a current ratio of 2.46, indicating that current assets are more than double current liabilities and providing a comfortable buffer against immediate obligations. Furthermore, the return on equity is -7.6% and the return on assets is -1.5%, metrics that reveal that management has not yet generated positive returns on the shareholders' capital or the total asset base during the current period.
バリュエーション評価
The valuation metrics show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 31.88, implying that the market is pricing in a future trajectory where earnings are expected to turn positive and expand significantly. The price-to-book ratio sits at 6.22, indicating that the market values the company at more than six times its book value, which suggests a high premium assigned to its intangible assets, intellectual property, and future growth potential rather than current tangible net worth. Alternative valuation measures such as a price-to-sales ratio of 4.49 and an EV/EBITDA of 147.24 further highlight that investors are willing to pay a steep multiple for revenue and earnings power, reflecting high expectations for the recovery of profitability. In terms of price action, the stock has a 52-week high of $170.87 and a 52-week low of $55.17, meaning the current trading price sits at a specific point within this wide range, reflecting significant volatility over the past year. The beta of 2.19 indicates that the stock's price volatility is more than double that of the broader market, suggesting it will experience amplified movements during periods of general market turbulence.
Growth & Income
Revenue growth for the trailing twelve months stands at 26.5%, demonstrating a robust expansion in top-line sales, whereas earnings growth is listed as N/A due to the current negative net income, implying that revenue expansion has not yet translated into bottom-line profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available earnings are theoretically available for reinvestment into the business rather than being distributed to shareholders. Since the firm is not a dividend payer, the capital generated from operations is effectively retained to fuel the development of its AI-based sequencing platforms and to cover the operating deficits until profitability is restored. The overall growth and income profile is characterized by strong top-line momentum and significant reinvestment of cash flows, though the lack of current earnings growth and dividend income reflects the transitional phase the company is currently undergoing in its financial performance.